title: VPA-induced recurrent pancreatitis in a cystic fibrosis carrier.
abstract: A 4.5 years old male with myoclonic epilepsy on Valproic acid (VPA) monotherapy, developed an acute pancreatitis. The discontinuation of VPA and substitution with Levetiracetam was followed by clinical improvement but a relapse of the pancreatitis was noted one month later. The investigation excluded a structural abnormality but revealed a heterozygous CTFR mutation. The contribution of the CTFR mutation on this VPA-induced recurrent pancreatitis cannot be ignored.
authors.affiliation: Attiko University Hospital, University of Athens, 3rd Dept of Pediatrics, Haidari, Greece. argidino@yahoo.com
authors.forename: Argirios
authors.initials: A
authors.lastname: Dinopoulos
authors.forename: Olga
authors.initials: O
authors.lastname: Karapanou
authors.forename: Efi
authors.initials: E
authors.lastname: Alexopoulou
authors.forename: Maria
authors.initials: M
authors.lastname: Tzetis
authors.forename: Achileas
authors.initials: A
authors.lastname: Attilakos
authors.forename: Andreas
authors.initials: A
authors.lastname: Fretzayas
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects*; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000235:genetics*; D004831:Epilepsies, Myoclonic / Q000188:drug therapy* / Q000235:genetics; D006580:Genetic Carrier Screening; D006801:Humans; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000235:genetics; D014463:Ultrasonography; D014635:Valproic Acid / Q000009:adverse effects*
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid